Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Acq. announced

Comera Life Sciences Holdings, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
10/10/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
10/10/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
10/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "12 Gill Street Suite 4650 ∙ Woburn MA 01801"
10/02/2023 8-K Quarterly results
09/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/25/2023 4 Cherington Charles (10% Owner) has filed a Form 4 on Comera Life Sciences Holdings, Inc.
Txns: Bought 880,195 shares @ $0.5113, valued at $450k
Bought 2,200,488 options to buy @ $0.6135, valued at $1.3M
08/24/2023 SC 13G Singer Nicholas Jason reports a 5.2% stake in Comera Life Sciences Holdings, Inc.
08/16/2023 SC 13G OTR Acquisition Sponsor LLC reports a 2.9% stake in Comera Life Sciences Holdings, Inc.
08/15/2023 4 Mahoney Robert Patrick (Chief Scientific Officer) has filed a Form 4 on Comera Life Sciences Holdings, Inc.
Txns: Bought 20,000 shares @ $0.6252, valued at $12.5k
08/15/2023 4 Wexler William A. (Director) has filed a Form 4 on Comera Life Sciences Holdings, Inc.
Txns: Acquired 6,636 shares @ $0
08/11/2023 ARS Form ARS - Annual Report to Security Holders:
08/11/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/10/2023 8-K Quarterly results
Docs: "Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights – Advanced to final stage of technical evaluation in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company – –Received notice that Nasdaq granted Comera’s request for the continued listing of its common stock, subject to Comera’s satisfaction of certain conditions – – Strengthened cash position with execution of a definitive agreement in July to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – – Significantly expanded intellectual property portfolio, broadening both geographic coverage and claims for core SQore™ excipient technology – WOBURN, M..."
08/10/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/10/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/10/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 SC 13G IAF, LLC reports a 9.9% stake in Comera Life Sciences Holdings, Inc.
08/07/2023 D Form D - Notice of Exempt Offering of Securities:
08/07/2023 D Form D - Notice of Exempt Offering of Securities:
08/02/2023 4 Soane David (10% Owner) has filed a Form 4 on Comera Life Sciences Holdings, Inc.
Txns: Bought 136,919 shares @ $0.5112, valued at $70k
Bought 136,919 shares @ $0.5112, valued at $70k
Bought 342,298 warrants @ $0.6135, valued at $210k
Bought 342,298 warrants @ $0.6135, valued at $210k
08/01/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
08/01/2023 8-K Quarterly results
05/19/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/19/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/19/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/19/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/16/2023 4 Wexler William A. (Director) has filed a Form 4 on Comera Life Sciences Holdings, Inc.
Txns: Granted 27,472 options to buy @ $0.69, valued at $19k
05/16/2023 4 RANDLE STUART A (Director) has filed a Form 4 on Comera Life Sciences Holdings, Inc.
Txns: Granted 56,662 options to buy @ $0.69, valued at $39.1k
05/16/2023 4 FLOWERS KIRSTEN (Director) has filed a Form 4 on Comera Life Sciences Holdings, Inc.
Txns: Granted 39,491 options to buy @ $0.69, valued at $27.2k
05/16/2023 4 Sullivan Edward Aloysius Jr. (Director) has filed a Form 4 on Comera Life Sciences Holdings, Inc.
Txns: Granted 44,642 options to buy @ $0.69, valued at $30.8k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy